Welcome to our dedicated page for Scribe Therapeutics SEC filings (Ticker: SCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Scribe Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Scribe Therapeutics's regulatory disclosures and financial reporting.
Scribe Therapeutics, Inc. (SCTX) reported that for the six months ended June 30, 2026 it generated $4.2 million in collaboration revenue, down sharply from $22.0 million a year earlier, and recorded a net loss of $23.8 million versus $13.3 million in the prior-year period.
Total operating expenses declined, with research and development falling to $20.1 million and general and administrative to $5.8 million, but lower collaboration revenue and fair-value changes on a convertible note increased overall losses. Cash, cash equivalents and investments were $43.0 million at June 30, 2026, before financing events.
Subsequent to quarter-end, Scribe completed an IPO and a concurrent private placement, raising approximately $140.7 million in net proceeds, and now expects its capital to fund operations into the first half of 2029. The company also secured up to $25.7 million in multi‑year CIRM grants to support its cardiometabolic gene-editing programs STX‑1200 and STX‑1400.
Scribe Therapeutics, Inc. (SCTX) reported second quarter 2026 results and highlighted major strategic milestones, including initiation of a first-in-human Phase 1 trial of lead LDL-C lowering candidate STX-1150 and completion of an upsized IPO plus a concurrent private placement to Sanofi.
Collaboration revenue for the quarter was $1.9 million, down from $4.9 million a year earlier, while research and development expenses fell to $8.8 million from $13.9 million. Net loss narrowed to $6.5 million, or $2.62 per share, compared with a $9.9 million loss, or $4.08 per share, in the prior-year period. Cash, cash equivalents and marketable securities were $43.0 million as of June 30, 2026.
The company raised approximately $155.5 million in aggregate gross proceeds from its July 2026 IPO and the Sanofi private placement and expects that, together with existing cash and investments, this will fund operations into the first half of 2029. Scribe also secured more than $25 million in non-dilutive grants from CIRM to advance cardiometabolic programs STX-1200 and STX-1400 toward potential clinical entry as early as 2027.
Avoro Capital Advisors LLC, Avoro Ventures LLC and Behzad Aghazadeh report beneficial ownership of Scribe Therapeutics, Inc. common stock following the company’s IPO. Collectively, the reporting persons beneficially own 3,088,888 shares of common stock, representing 16.37% of the outstanding class based on 18,864,386 shares outstanding after the IPO and a concurrent private placement.
Holdings arose from automatic conversion of Series B preferred stock at IPO closing, purchases of 2,333,333 shares from the underwriters at $15.00 per share, and additional open-market purchases. The funds are party to an Amended and Restated Investors’ Rights Agreement providing registration rights and customary lock-up provisions. Separate lock-up agreements generally restrict transfers for 180 days after the IPO prospectus date, extended by the issuer to September 28, 2026, with limited exceptions. Dr. Aghazadeh serves on Scribe’s board and received an option for 14,725 shares at a $15.00 exercise price, vesting annually over three years.
Eli Lilly and Company reported a significant equity position in Scribe Therapeutics, Inc., holding 1,388,161 shares of common stock. This represents approximately 7.36% of Scribe’s outstanding common shares, based on 18,864,386 shares outstanding after Scribe’s IPO and full exercise of the underwriters’ option.
Lilly’s stake consists of 1,054,828 shares issued upon conversion of an 8% Convertible Promissory Note previously purchased for $30.0 million, plus 333,333 shares bought in the IPO at $15.00 per share (about $5.0 million). Lilly states the position is for investment purposes, while reserving the flexibility to increase, reduce, or hedge its holdings over time. Lilly also entered into a 180‑day lock-up agreement from July 23, 2026, restricting sales or transfers without underwriters’ consent.
Scribe Therapeutics (SCTX) insider filings report that entities associated with Avoro Capital Advisors and Avoro Ventures indirectly purchased 2,391,238 shares of Common Stock. This includes 2,333,333 shares bought in the IPO at $15.00 per share and additional open‑market purchases at $22.31 and $18.25 per share on behalf of Avoro Life Sciences Fund LLC and Avoro Ventures Fund L.P. The shares are held by these funds, with the reporting persons potentially deemed beneficial owners through advisory and control roles and disclaiming beneficial ownership beyond their pecuniary interest. Total reported indirect holdings include 3,088,888 shares, of which 697,650 arose from the automatic conversion of Series B Preferred Stock into Common Stock upon the IPO closing.
Scribe Therapeutics, Inc. reported that President, CEO and Chairman Benjamin L. Oakes received three option awards for its common stock. On March 13, 2026, he was granted 12,969 options with a $19.13 exercise price, which are fully vested. On July 23, 2026, he received a time-based option for 264,784 shares at $15.00 per share, vesting in equal monthly installments over four years starting August 23, 2026, and a performance-based option for 429,599 shares at $15.00 per share, eligible to vest upon specified market-based performance criteria during a period from July 23, 2026 to July 23, 2029. The July 2026 grants expire on July 22, 2036, and the March 2026 grant expires on March 12, 2036.
Scribe Therapeutics, Inc. director James Dean Watson received a grant of stock options for 14,725 shares of Common Stock on July 23, 2026. These options have a conversion/exercise price of $15.00 per share and expire on July 22, 2036. Following this grant, he holds options for 14,725 shares directly.
The options will vest in three equal installments of one-third of the total shares on July 23, 2027, July 23, 2028, and July 23, 2029, subject to his continued service to Scribe Therapeutics on each vesting date.
Scribe Therapeutics, Inc. director Joshua Bleharski received a grant of stock options for 14,725 shares of common stock on July 23, 2026. The options have an exercise price of $15.00 per share and expire on July 22, 2036. They vest in three equal annual installments on July 23 of 2027, 2028, and 2029, contingent on continued service.
Scribe Therapeutics, Inc. Chief Financial Officer David Parrot reported multiple equity awards and open-market purchases. On July 23, 2026 he received stock options for 109,426 shares at $15.00 per share that vest monthly over four years, plus performance-based options for 109,426 shares at $15.00 that may vest between July 23, 2026 and July 23, 2029 based on market-based criteria. He also reported indirect open-market purchases of 1,333 common shares for a spouse and 1,333 shares for a child at $15.00 per share. A prior option grant for 8,909 shares at $19.13, fully vested and expiring March 12, 2036, was also disclosed under Rule 16a-2(a) in connection with the company’s initial public offering.
Scribe Therapeutics, Inc. reported that Dr. Behzad Aghazadeh and affiliated entities Avoro Capital Advisors LLC and Avoro Ventures LLC received a grant of 14,725 stock options to purchase Common Stock. The options carry a $15.00 exercise price and expire on July 22, 2036. They vest in three equal installments on July 23, 2027, July 23, 2028, and July 23, 2029, subject to Dr. Aghazadeh’s continued service. The reporting persons expressly disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.